Corcept Therapeutics

Press Releases

Date Title
07/01/10 Corcept Therapeutics Completes Enrollment in Phase 3 Cushing's Syndrome Study - Data Announcement Anticipated by Year End
06/25/10 Corcept Therapeutics Nears Completion of Enrollment in Phase 3 Cushing's Syndrome Study - Data Announcement Anticipated by Year End
05/11/10 Corcept Therapeutics Announces First Quarter Results and Update on Development Programs
05/03/10 Corcept Therapeutic Updates Cushing's Syndrome Development and Recent Financing
04/22/10 Corcept Therapeutics Announces Exercise of Existing Warrants and Private Placement of Warrants
03/25/10

Corcept Therapeutics Announces Fourth Quarter and Full Year 2009 Results and Update on Development Programs

02/23/10 Corcept Therapeutics Initiates a Phase 1 Study of Its Lead Selective Cortisol Receptor (GR-II) Antagonist -- CORT 108297
01/05/10 Corcept Therapeutics Announces Four Anticipated Milestones for 2010
11/10/09 Corcept Therapeutics Announces Recent Highlights and Third Quarter 2009 Financial Results
10/13/09 Corcept Therapeutics Announces Pricing of Private Placement Cash Sufficient to Fund Company through Corlux NDA Submission
08/11/09 Corcept Therapeutics Announces Second Quarter 2009 Results and Development Highlights
05/11/09 Corcept Therapeutics Announces First Quarter 2009 Results and Development Highlights
03/30/09 Corcept Therapeutics Announces Fourth Quarter and Full Year 2008 Results and Update on Development Programs
02/23/09

Data Demonstrates Metabolic Benefits of Adding Corlux® to Treatment with Risperdal®

02/02/09

Corlux Mitigates Weight Gain Associated with Risperdal Expands on Proof of Concept Established in Earlier Trials

01/09/09

Trials Show Next-Generation GRII Receptor Antagonist Prevents and Reverses Weight Gain Associated with Use of Olanzapine - the Active Ingredient in Zyprexa®

12/02/08

Caroline Loewy Joins Corcept as Chief Financial Officer

11/13/08

Corcept Therapeutics Announces Third Quarter 2008 Results

09/03/08

Corcept Therapeutics Continues Collaboration with Eli Lilly and Company

08/13/08

Corcept Therapeutics Announces Second Quarter 2008 Results

05/12/08

Corcept Therapeutics Announces First Quarter 2008 Results

05/01/08 Corcept Therapeutics Announces Promising Results of Human Microdosing Study of Selective GR-II Antagonist
03/27/08

Corcept Therapeutics Announces Fourth Quarter 2007 Results

03/26/08

Corcept Therapeutics Completes $25 Million Private Equity Financing and Secures Committed Equity Financing Facility for up to $60 Million

03/24/08

Corcept Therapeutics Announces Commencement of Next Phase 3 Study with Corlux for the Treatment of Psychotic Depression. Agreement Signed with MedAvante, Inc.

03/17/08

Corcept Therapeutics Announces $25.3 Million Private Equity Financing

09/25/07

Corcept Therapeutics Completes Second Closing Under August Private Equity Financing Agreement

09/11/07 Corcept Therapeutics Receives FDA Notification Opening IND for Corlux® for the Treatment of Cushing's Syndrome
08/20/07

Corcept Therapeutics Announces $10.1 Million Private Equity Financing

08/13/07

Corcept Therapeutics Announces Second Quarter 2007 Results

07/25/07

Corcept Therapeutics and Xceleron Sign Agreement for Microdosing Study Using Accelerator Mass Spectrometry

07/09/07

Corcept Therapeutics Receives Orphan Drug Designation for Corlux® Treatment of Cushing's Syndrome

06/21/07 Corcept Therapeutics Announces Positive Results from its Proof of Concept Study Evaluating the Ability of CORLUX® to Mitigate Weight Gain Associated
With Olanzapine
05/14/07

Corcept Therapeutics Announces First Quarter 2007 Results

04/04/07

Nasdaq Panel Grants Corcept Therapeutics' Request for Listing on the Nasdaq Capital Market

03/30/07

Corcept Therapeutics Announces $9 Million Private Equity Financing

03/28/07

Corcept Therapeutics Announces Chief Financial Officer Resignation

03/28/07

Corcept Therapeutics Announces Fourth Quarter 2006 Results

03/19/07

Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for Psychotic Major Depression Misses Primary Endpoint

01/16/07

Corcept Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

12/27/06

Corcept Therapeutics Receives Nasdaq Notice of Non-Compliance. Company Appeals to Nasdaq Listing Qualifications Panel

12/15/06 Corcept Therapeutics Completes $3 Million Private Equiity Financing
11/17/06

Corcept Therapeutics Receives Nasdaq Delisting Notification

11/15/06

Corcept Therapeutics Announces $3 Million Private Equity Financing

11/13/06

Corcept Therapeutics Completes Enrollment in Third Phase 3 Study for Treating Psychotic Major Depression

11/8/06

Corcept Therapeutics Announces Third Quarter 2006 Results

9/29/06 Corcept Therapeutics Announces Negative Results from the Second of Three Phase 3 Studies Evaluating Corlux® for Treating the Psychotic Features of Psychotic Major Depression
9/11/06

Corcept Therapeutics to present at Merriman Curhan Ford 3rd Annual Investor Summit on September 18, 2006

9/05/06 Corcept Therapeutics to present at Bear Stearns 19th Annual Healthcare Conference on September 12, 2006
8/30/06

Corcept Therapeutics to present at Thomas Weisel Partners Healthcare Conference on September 7, 2006

8/25/06

Corcept Therapeutics Announces Negative Results from the First of Three Phase 3 Studies Evaluating Corlux® for Treating the Psychotic Features of Psychotic Major Depression

8/10/06

Corcept Therapeutics Announces Second Quarter 2006 Results

8/7/06

Corcept Therapeutics Announces Publication of Phase 2 Clinical Study Results in the Journal of Biological Psychiatry

7/7/06 Corcept Therapeutics to Present at C.E. Unterberg, Towbin
Emerging Growth Conference on July 11, 2006
5/22/06

Corcept Therapeutics Completes Enrollment in Second Phase 3 Study for Treating Psychotic Major Depression

5/09/06 Corcept Therapeutics Announces First Quarter 2006 Results
5/01/06 Corcept Therapeutics Completes Enrollment in Phase 3 Study for Treating Psychotic Major Depression
3/08/06

Corcept Therapeutics Announces Fourth Quarter 2005 Results

2/06/06

Corcept Therapeutics Announces Allowance of European Patent Covering Use of GR-II Antagonists to Treat the Psychotic Features of Psychotic Major Depression

11/08/05 Corcept Therapeutics Announces Third Quarter 2005 Results
11/02/05 Corcept Therapeutics to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference on November 9, 2005
10/21/05

Lilly to Support Corcept's Clinical Study Evaluating the Ability of a GR-II Antagonist to Mitigate the Weight Gain Associated with Use of Atypical Antipsychotic Medications

10/19/05 Corcept Therapeutics to Present at C.E. Unterberg, Towbin
Emerging Growth Life Sciences Conference on October 26, 2005
09/26/05 Corcept Announces Revised Reporting Dates for One of Its Three Phase III Clinical Trials
09/26/05 Corcept Closes Enrollment of Proof of Concept Clinical Study Evaluating Corlux® in Alzheimer's Disease
08/31/05 Corcept Therapeutics to Present at Thomas Weisel Partners Healthcare Conference on September 7, 2005
08/9/05

Corcept Therapeutics Announces Second Quarter 2005 Results

06/8/05 Corcept Therapeutics to Present at Thomas Weisel Partners Growth Forum on June 13, 2005
05/11/05

Corcept Therapeutics Announces First Quarter 2005 Results

05/04/05

Corcept Therapeutics Initiates Third Phase III Trial of Corlux®

04/18/05

Corcept Preclinical Trials Show Corlux® Prevents Weight Gain Associated with Use of Olanzapine, the Active Ingredient in Zyprexa®

03/03/05

Corcept Therapeutics Announces Fourth Quarter 2004 Results

02/22/05 Corcept Therapeutics to Present at Wells Fargo Securities HealthCare Forum on March 1, 2005
12/06/04 Corcept Therapeutics to Present at Harris Nesbitt "Focus on Healthcare" Investor Conference on December 8, 2004
10/28/04

Corcept Therapeutics announces Third Quarter 2004 results

10/26/04

Corcept Therapeutics announces resolution of patent inventorship dispute

10/19/04 Corcept Therapeutics commences second pivotal Phase III clinical trial of Corlux
10/12/04 Corcept Therapeutics appoints James A. Harper to Board of Directors
8/30/04

Corcept Therapeutics receives special protocol assessment from FDA for two pivotal Phase III trials of Corlux™

8/9/04 Corcept Therapeutics announces Second Quarter Results
7/26/04 Corcept Therapeutics appoints David L. Mahoney to Board of Directors
5/26/04 Corcept Therapeutics announces First Quarter 2004 Results
5/3/04 Corcept Therapeutics presents results of clinical study at the 59th Annual Society of Biological Psychiatry Conference
4/14/04 Corcept Therapeutics announces Initial Public Offering
2/10/04 Corcept Therapeutics files registration statement for Initial Public Offering

The documents contained in this website include forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995) that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included on this web site regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. There are a number of important factors that could cause Corcept's actual results to differ materially from those indicated by such forward-looking statements. You should consult our Registration on Form S-1 and subsequent reports filed with the SEC. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date any such statement was first made.